A randomized controlled clinical trial has shown that the dipeptidyl peptidase-4 inhibitor sitagliptin may support the healing of diabetic foot ulcers through mechanisms that extend beyond glucose control. The study compared patients receiving standard conventional therapy alone with those who received sitagliptin in addition to standard care. The main outcomes examined included ulcer healing, safety, time to healing, changes in circulating endothelial progenitor cells, levels of stromal cell derived factor-1 alpha, and glycosylated hemoglobin. Findings demonstrated that patients treated with sitagliptin experienced greater reductions in ulcer size and overall improvement in wound healing compared to those on conventional therapy alone. The sitagliptin group also showed an increase in circ

See Full Page